2018
Trajectories after first‐episode psychosis: Complement to ambiguous outcomes of long‐term antipsychotic treatment by exploring a few hidden cases
Liu C, Lin Y, Liu C, Hsieh M, Chien Y, Hwang T, Hwu H. Trajectories after first‐episode psychosis: Complement to ambiguous outcomes of long‐term antipsychotic treatment by exploring a few hidden cases. Early Intervention In Psychiatry 2018, 13: 895-901. PMID: 29927087, DOI: 10.1111/eip.12696.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisLong-term antipsychotic treatmentAntipsychotic treatmentRecurrence of psychotic symptomsCourse of chronic schizophreniaLow-dose antipsychoticsChronic schizophreniaDysthymic statesPsychotic symptomsDiagnostic stabilityWord lettersRemission criteriaPsychosisAmbiguous informationProbability of relapseCoping strategiesImpending relapseAmbiguous outcomesDiscontinued medicationAntipsychoticsPersonalized formulationsMedication adherencePsychosocial factorsEarly interventionGroup of patients
2016
Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
Garay R, Citrome L, Samalin L, Liu C, Thomsen M, Correll C, Hameg A, Llorca P. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opinion On Pharmacotherapy 2016, 17: 921-936. PMID: 26831200, DOI: 10.1517/14656566.2016.1149164.Peer-Reviewed Original ResearchConceptsCognitive impairment associated with schizophreniaSchizoaffective disorderNegative symptomsDopamine D2 receptor partial agonistTreatment of cognitive impairment associated with schizophreniaD2 receptor partial agonistTreating positive symptomsReceptor partial agonistEU clinical trial registriesAdd-on compoundsTardive dyskinesiaPositive symptomsGoal of recoverySchizophreniaPartial agonistAntipsychoticsSchizoaffectivePhase III of clinical developmentTherapeutic improvementDisordersClinical Trials RegistrySymptomsPharmacodynamic profileClinical developmentAcademic medical center